BIO-PATH HOLDINGS, INC.
BIO-PATH HOLDINGS, INC. (BPTH): 4 pipeline candidates · ~17 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
16.7 months
D/E -1.08 · 0% dilution
Lead: Phase 2
4 candidates
N/A
N/A
A transparent, data-derived signal for BIO-PATH HOLDINGS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.8M
Cash
$12K
Quarterly Burn
$38K
Runway
16.7 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
Frequently asked questions
How many drug candidates are in BIO-PATH HOLDINGS, INC.'s pipeline?
BIO-PATH HOLDINGS, INC. (BPTH) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is BIO-PATH HOLDINGS, INC.'s lead drug candidate?
BIO-PATH HOLDINGS, INC.'s most advanced tracked candidate is BP1001 (Phase 2) for Acute Myeloid Leukemia (AML).
What is BIO-PATH HOLDINGS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, BIO-PATH HOLDINGS, INC. has approximately 16.7 months of cash runway.
What is BIO-PATH HOLDINGS, INC.'s market capitalization?
BIO-PATH HOLDINGS, INC.'s market capitalization is approximately $1.8M.
Who is the CEO of BIO-PATH HOLDINGS, INC.?
Mr. Vikram Paul Grover C.F.A., Esq. is the chief executive officer of BIO-PATH HOLDINGS, INC. (BPTH).
Get the full picture on BIO-PATH HOLDINGS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.